Immune Globulin Intravenous

BIOLOGICAL4 trials

Sponsors

Prometic Biotherapeutics, Inc., Monash University

Conditions

LeukemiaMyelomaNon Hodgkin's LymphomaPrimary Immunodeficiency

Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

RecruitingNCT07202065

Monash UniversityLeukemia, Myeloma, Non Hodgkin's Lymphoma

Start: 2025-04-28End: 2027-03-31Target: 900Updated: 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

RecruitingNCT07202091

Monash UniversityLeukemia, Myeloma, Non Hodgkin's Lymphoma

Start: 2025-05-06End: 2027-03-31Target: 900Updated: 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

RecruitingNCT07202078

Monash UniversityLeukemia, Myeloma, Non Hodgkin's Lymphoma

Start: 2025-05-07End: 2027-03-31Target: 900Updated: 2025-10-07

Phase 3

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

CompletedNCT02269163

Prometic Biotherapeutics, Inc.Primary Immunodeficiency

Start: 2016-01-26End: 2019-01-11Updated: 2021-11-05